Short communicationPublished 25 Jun 2021
MicroRNA-124-3p-enriched small extracellular vesicles as a promising therapeutic approach for Parkinson?s disease.
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Parkinson’s disease (PD), a neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra (SN), does not yet have an effective cure available. MicroRNA-124 (miR-124) has been regarded as a novel therapeutic entity for PD due to its pro-neurogenic and neuroprotective roles. However, its efficient delivery to the brain remains challenging. Previously, we have developed polymeric nanoparticles to deliver miR-124 in the brain. These miR-124-loaded nanoparticles were able to boost subventricular zone (SVZ) neurogenesis in vitro and in vivo and, ultimately, ameliorated motor deficits in a PD mouse model. Here, we used umbilical cord blood mononuclear cell-derived small extracellular vesicles as a biological vehicle to deliver miR-124 (miR-124 sEVs) to the brain, and its therapeutic effects were then evaluated in a 6-hydroxydopamine (6-OHDA) mouse model of PD. In vitro, miR-124 sEVs induced neurogenesis in SVZ neural stem cell cultures and protected N27 cells against 6-OHDA-induced toxicity. In vivo, intracerebroventricularly administered sEVs were found in the SVZ lining the lateral ventricles, striatum, and SN, the brain regions most affected by PD.
Keywords
Subjects
EngineeringAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInternational Journal of Innovative Research in Science, Engineering and Technology
- SubjectEngineering
- BylineArticles whose byline prints “Liliana Bernardino”
